Prialt
Total Payments
$1.6M
Transactions
11,437
Doctors
2,550
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $335,247 | 1,964 | 737 |
| 2023 | $109,576 | 1,581 | 697 |
| 2022 | $139,649 | 1,452 | 634 |
| 2021 | $33,048 | 872 | 461 |
| 2018 | $397,413 | 1,922 | 723 |
| 2017 | $597,658 | 3,646 | 1,010 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $529,422 | 183 | 32.8% |
| Consulting Fee | $474,682 | 326 | 29.4% |
| Food and Beverage | $244,545 | 9,217 | 15.2% |
| Travel and Lodging | $153,313 | 503 | 9.5% |
| Unspecified | $115,862 | 42 | 7.2% |
| Education | $73,767 | 1,161 | 4.6% |
| Grant | $10,000 | 2 | 0.6% |
| Honoraria | $8,000 | 2 | 0.5% |
| Space rental or facility fees (teaching hospital only) | $3,000 | 1 | 0.2% |
Payments by Type
General
$1.5M
11,395 transactions
Research
$115,862
42 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Prospective Study of Prialt as a First-Line Intrathecal Drug Therapy | Jazz Pharmaceuticals Inc. | $23,998 | 0 |
| Patient Registry of Intrathecal Ziconotide ManagementPRIZM PRIZM | Jazz Pharmaceuticals Inc. | $18,728 | 3 |
| Prospective study of conservative Ziconotide dosing as a first line intrathecal drug therapy for neuropathic pain | Jazz Pharmaceuticals Inc. | $18,625 | 0 |
| IIR- Protocol SCAS-SPA-2016-02 Stability Protocol forPrialt 25 gmL Solution inFlowonix Pump Reservoirs | Jazz Pharmaceuticals Inc. | $15,850 | 0 |
| STABILITY PROTOCOL FOR PRIALT 25 ML SOLUTION INFLOWONIXPUMPRESERVOIRS | Jazz Pharmaceuticals Inc. | $15,850 | 0 |
| The efficacy of Ziconotide in treatment of Vincristine Induced Neuropathy | Jazz Pharmaceuticals Inc. | $9,948 | 0 |
| Patient Registry of Intrathecal Ziconotide ManagementPRIZM | Jazz Pharmaceuticals Inc. | $9,284 | 1 |
| Retrospective Analysis of Prialt as a First-Line Intrathecal Drug Therapy | Jazz Pharmaceuticals Inc. | $3,580 | 0 |
Top Doctors Receiving Payments for Prialt — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Pain Medicine | Irvine, CA | $873.16 | 28 |
| , D.O | Anesthesiology | Defiance, OH | $818.45 | 23 |
| , MD | Physical Medicine & Rehabilitation | Hermitage, TN | $811.36 | 22 |
| , P.A.-C | Physician Assistant | Webster, TX | $798.32 | 38 |
| , RN-BC, ANP-C | Adult Health | Webster, TX | $793.30 | 38 |
| , MD | Neurological Surgery | Orange, CA | $789.61 | 18 |
| , M.D.,DABPM | Anesthesiology | New Haven, CT | $766.62 | 32 |
| , MD | Anesthesiology | Clearwater, FL | $765.34 | 27 |
| , MD | Anesthesiology | Fairfield, OH | $764.49 | 24 |
| , PA-C | Physician Assistant | Washington, PA | $759.27 | 32 |
| , DO | Physical Medicine & Rehabilitation | Orlando, FL | $725.00 | 32 |
| , M.D | Anesthesiology | Kenosha, WI | $716.74 | 21 |
| , MD | Pain Medicine | Caldwell, ID | $685.26 | 16 |
| , MD | Pain Medicine | San Luis Obispo, CA | $684.19 | 13 |
| , M.D | Physical Medicine & Rehabilitation | Fort Wayne, IN | $683.32 | 16 |
| , M.D | Pain Medicine | Los Alamitos, CA | $671.48 | 21 |
| , MD | Interventional Pain Medicine | New Hyde Park, NY | $663.37 | 34 |
| , M.D | Interventional Pain Medicine | Oshkosh, WI | $648.00 | 1 |
| , M.D | Specialist | San Luis Obispo, CA | $639.20 | 13 |
| , D.O | Pain Medicine | Mission Viejo, CA | $624.91 | 25 |
| , MD | Pain Medicine | Flint, MI | $618.13 | 11 |
| , M. D | Anesthesiology | Jackson, TN | $616.58 | 14 |
| , MD | Pain Medicine | Temecula, CA | $611.02 | 17 |
| , MD | Pain Medicine | Fort Myers, FL | $610.65 | 26 |
| , MD | Anesthesiology | Troy, MO | $603.46 | 19 |
Ad
Manufacturing Companies
- Jazz Pharmaceuticals Inc. $986,487
- TerSera Therapeutics LLC $626,104
Product Information
- Type Drug
- Total Payments $1.6M
- Total Doctors 2,550
- Transactions 11,437
About Prialt
Prialt is a drug associated with $1.6M in payments to 2,550 healthcare providers, recorded across 11,437 transactions in the CMS Open Payments database. The primary manufacturer is Jazz Pharmaceuticals Inc..
Payment data is available from 2017 to 2024. In 2024, $335,247 was paid across 1,964 transactions to 737 doctors.
The most common payment nature for Prialt is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($529,422, 32.8% of total).
Prialt is associated with 8 research studies, including "Prospective Study of Prialt as a First-Line Intrathecal Drug Therapy" ($23,998).